Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

被引：0
|
作者：
Rong Shi
Tong Lu
Grace Ku
Hao Ding
Tomohisa Saito
Leonid Gibiansky
Priya Agarwal
Xiaobin Li
Jin Yan Jin
Sandhya Girish
Dale Miles
Chunze Li
Dan Lu
机构：
[1] Genentech Inc.,
[2] Chugai Pharmaceutical Co.,undefined
[3] Ltd.,undefined
[4] QuantPharm LLC,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Ethnic sensitivity assessment; NHL; Non-hodgkin lymphoma; PK; Polatuzumab vedotin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：347 / 359
页数：12
相关论文
共 50 条
  • [1] Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
    Shi, Rong
    Lu, Tong
    Ku, Grace
    Ding, Hao
    Saito, Tomohisa
    Gibiansky, Leonid
    Agarwal, Priya
    Li, Xiaobin
    Jin, Jin Yan
    Girish, Sandhya
    Miles, Dale
    Li, Chunze
    Lu, Dan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (03) : 347 - 359
  • [2] Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Dere, Randall C. C.
    Beardsley, Richard L. L.
    Lu, Dan
    Lu, Tong
    Ku, Grace H-W.
    Man, Gabriel
    Nguyen, Van
    Kaur, Surinder
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma
    Varma, Gaurav
    Wang, Jacqueline
    Diefenbach, Catherine
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 795 - 803
  • [4] Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
    Kinoshita, Tomohiro
    Hatake, Kiyohiko
    Yamamoto, Kazuhito
    Higuchi, Yusuke
    Murakami, Satsuki
    Terui, Yasuhito
    Yokoyama, Masahiro
    Maruyama, Dai
    Makita, Shinichi
    Hida, Yukari
    Saito, Tomohisa
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (01) : 70 - 77
  • [5] Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
    Colby S. Shemesh
    Priya Agarwal
    Tong Lu
    Calvin Lee
    Randall C. Dere
    Xiaobin Li
    Chunze Li
    Jin Y. Jin
    Sandhya Girish
    Dale Miles
    Dan Lu
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 831 - 842
  • [6] Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
    Shemesh, Colby S.
    Agarwal, Priya
    Lu, Tong
    Lee, Calvin
    Dere, Randall C.
    Li, Xiaobin
    Li, Chunze
    Jin, Jin Y.
    Girish, Sandhya
    Miles, Dale
    Lu, Dan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 831 - 842
  • [7] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [8] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [9] Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    Witzig, TE
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S91 - S95
  • [10] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
12345